viernes, 21 de octubre de 2011
Drug Safety and Availability > FDA Drug Safety Communication: Updated information about the drug interaction between linezolid (Zyvox) and serotonergic psychiatric medications
The U.S. Food and Drug Administration (FDA) is updating the public on the potential drug interaction between linezolid and serotonergic psychiatric medications.
FDA is providing additional information about the reports of serotonin syndrome. Not all serotonergic psychiatric drugs have an equal capacity to cause serotonin syndrome with linezolid. Most cases from the FDA's Adverse Event Reporting System (AERS) of serotonin syndrome with linezolid occurred in patients taking specific serotonergic psychiatric drugs, namely a selective serotonin reuptake inhibitor (SSRI) or a serotonin norepinephrine reuptake inhibitor (SNRI). It is unclear at this time whether linezolid administration in patients receiving other psychiatric drugs with lesser degrees of serotonergic activity poses a comparable risk.
FDA will update the public when new information is available.
For more information please visit: Zyvox:
open here please:
Drug Safety and Availability > FDA Drug Safety Communication: Updated information about the drug interaction between linezolid (Zyvox) and serotonergic psychiatric medications
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario